The purpose of the study is to evaluate the safety、tolerability and preliminary efficacy of B019 in subjects with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Subjects who can fully understand this trial and voluntarily sign the informed consent form (ICF) before any research-related procedures;
Histologically confirmed B-cell non-Hodgkin's lymphoma (B-NHL) with specified pathological subtypes;
Histologically confirmed CD19 and/or CD22 positivity;
Expected survival time exceeding 12 weeks;
Primary central nervous system (CNS) lymphoma; However, secondary CNS lymphoma without clinical symptoms can be enrolled after being determined by the researchers；
Use of the prescribed drugs or treatments within the specified time before the collection of PBMC;
Prior allogeneic hematopoietic stem cell transplantation;
Systemic intravenous infusion treatment or uncontrollable bacterial, fungal or viral infection within 2 weeks before signing the ICF;
Single group
B019
DrugB019： Intravenous infusion, 2.0×10\^6 cell/kg-8.0×10\^6 cell/kg
Dose-limiting toxicity (DLT)
Measurement of DLT of B019 in all subjects
MTD（Maximum tolerated dose）
Maximum tolerated dose
The overall response rate (ORR)
Tumor response will be evaluated according to the Lugano 2014 criteria.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
